Biotech companies at EBF 2026

Nov 17–19, 2026 Barcelona, Spain ~800 attendees Website

8 biotech companies are at EBF 2026 — 9 presentations on the program. Most represented: argenx (2 on the program), AC Immune (1 on the program), ADC Therapeutics (1 on the program). 1 of them have their own page in this guide. As of Oct 13, 2026.

All 63 organizations at EBF 2026 →

Showing 1–8 of 8 organizations

Organization	EBF 2026 Attendance
argenx
argenx.com Biotech Immunology biotech whose antibody efgartigimod treats generalized myasthenia gravis and other autoimmune diseases.	Talk Tue Nov 17 5:40–6pm Part of Session 7: BM CoU in practice From qualitative detection to quantitative insight: repurposing a diagnostic assay into a fit-for-purpose semi-quantitative titer assay as measure of treatment response Biomarkers Talk Wed Nov 18 11:40am–12pm Part of Session 14: Rethinking ADA Assessment, Context, Evidence and Evolving Expectations - part 2 A streamlined ADA testing strategy to assess the clinical immunogenicity of a biological drug entering clinical development Immunogenicity
AC Immune Lausanne, Switzerland
acimmune.com Biotech Clinical-stage biotech developing vaccines and antibodies against misfolded proteins in neurodegenerative diseases such as Alzheimer's and Parkinson's.	Talk Tue Nov 17 11:10–11:30am Part of Session 3: Vaccines Active immunotherapy responder determination in a population with potential pre-existing antibodies Vaccines · Immunogenicity
ADC Therapeutics Lausanne, Switzerland
adctherapeutics.com Biotech Develops antibody–drug conjugates for cancer, including a marketed ADC for lymphoma.	Talk Wed Nov 18 10–10:20am Part of Session 11: Rethinking ADA Assessment, Context, Evidence and Evolving Expectations - part 1 Clinical Relevance of ADC Immunogenicity: Are We Measuring What Matters? Immunogenicity · New modalities
BioNTech Mainz, Germany
biontech.com Biotech Develops mRNA vaccines and immunotherapies, including the COVID-19 vaccine developed with Pfizer, and cancer treatments.	Talk Thu Nov 19 12:30–12:50pm Part of Session 19: ADC Bioanalysis, From Community Recommendations to Complex PK Decisions Trust, but Verify: A Risk-Based Framework for Orthogonal LC-MS Investigation of Unexpected ADC Pharmacokinetic Profiles New modalities · LC–MS
Genmab Copenhagen, Denmark
genmab.com Biotech Antibody biotech developing bispecific antibodies and antibody–drug conjugates for cancer.	Talk Tue Nov 17 11:10–11:30am Part of Session 2: Smarter Workflows: From Implementation to Scientific Confidence Implementation of an End-to-End Automated Bioanalysis Workflow Automation & AI
Idorsia Allschwil, Switzerland
idorsia.com Biotech Biopharmaceutical company with marketed medicines for insomnia and hypertension.	Talk Thu Nov 19 3–3:20pm Part of Session 21: Protein MS Tech 2 Development and Clinical Application of a Fit-for-Purpose LC-MS/MS Assay for Quantification of CT-proET-1 in Human Plasma LC–MS · Biomarkers
MinervaX Copenhagen, Denmark
minervax.com Biotech Develops a protein-based maternal vaccine against group B streptococcus.	Talk Tue Nov 17 12:30–12:50pm Part of Session 3: Vaccines Strategies for validating functional titre based vaccine assays versus concentration based multiplex vaccine immunoassays for a multicomponent bacterial vaccine Vaccines
Regeneron Tarrytown, New York
regeneron.com Biotech Biotech developing antibody medicines for eye disease, inflammatory diseases, cancer and rare diseases.	Talk Tue Nov 17 12:30–12:50pm Part of Session 2: Smarter Workflows: From Implementation to Scientific Confidence One Well, Full Confidence: Automation-Enabled Singlicate Analysis for Regulated Bioanalysis Automation & AI